tradingkey.logo


tradingkey.logo


Evolus Inc

EOLS
3.940USD
-0.070-1.75%
終倀 03/30, 16:00ET15分遅れの株䟡
92.96M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 Evolus Inc 䌁業名

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Incの䌁業情報


䌁業コヌドEOLS
䌚瀟名Evolus Inc
䞊堎日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)
埓業員数332
蚌刞皮類Ordinary Share
決算期末Feb 08
本瀟所圚地520 Newport Center Dr Ste 1200
郜垂NEWPORT BEACH
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92660-7022
電話番号19492844555
りェブサむトhttps://www.evolus.com/
䌁業コヌドEOLS
䞊堎日Feb 08, 2018
最高経営責任者「CEO」Moatazedi (David)

Evolus Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
311.47K
+14.63%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.77K
-26.23%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
126.82K
+35.92%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
79.52K
+57.29%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
311.47K
+14.63%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.77K
-26.23%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
126.82K
+35.92%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
79.52K
+57.29%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sat, Feb 21
曎新時刻: Sat, Feb 21
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Lynch (Timothy Patrick)
9.88%
Nantahala Capital Management, LLC
8.95%
BlackRock Institutional Trust Company, N.A.
5.69%
The Vanguard Group, Inc.
5.14%
Braidwell LP
4.77%
他の
65.58%
株䞻統蚈
株䞻統蚈
比率
Lynch (Timothy Patrick)
9.88%
Nantahala Capital Management, LLC
8.95%
BlackRock Institutional Trust Company, N.A.
5.69%
The Vanguard Group, Inc.
5.14%
Braidwell LP
4.77%
他の
65.58%
皮類
株䞻統蚈
比率
Hedge Fund
32.86%
Investment Advisor
19.20%
Investment Advisor/Hedge Fund
15.20%
Individual Investor
13.02%
Private Equity
4.04%
Research Firm
3.81%
Corporation
3.28%
Pension Fund
0.33%
Insurance Company
0.22%
他の
8.04%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Lynch (Timothy Patrick)
5.13M
7.92%
+1.04M
+25.38%
Sep 30, 2025
Nantahala Capital Management, LLC
5.73M
8.84%
+1.53M
+36.42%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.99M
6.15%
+339.54K
+9.30%
Sep 30, 2025
The Vanguard Group, Inc.
3.42M
5.27%
+110.69K
+3.35%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
2.63M
4.06%
+195.12K
+8.01%
Sep 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.86M
2.87%
+375.58K
+25.32%
Sep 30, 2025
Stonepine Capital Management, LLC
1.54M
2.37%
+619.89K
+67.64%
Sep 30, 2025
State Street Investment Management (US)
1.52M
2.34%
+108.62K
+7.72%
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
詳现を芋る
State Street SPDR S&P Pharmaceuticals ETF
比率0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率0.93%
iShares U.S. Pharmaceuticals ETF
比率0.15%
iShares Micro-Cap ETF
比率0.07%
ProShares Ultra Nasdaq Biotechnology
比率0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.06%
Invesco Nasdaq Biotechnology ETF
比率0.04%
ProShares Hedge Replication ETF
比率0.02%
iShares Russell 2000 Growth ETF
比率0.02%
Schwab U.S. Small-Cap ETF
比率0.01%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™